BackEucrates Biomedical Acquisition Overview

Eucrates Biomedical Acquisition Receivables

Eucrates Biomedical Acquisition's receivables is $0.

Get informed when a big investor buys or sells

+ Follow
Receivables
$0.00

Peer trimmed avg / median

Loading

Eucrates Biomedical Acquisition Receivables History

Loading

Eucrates Biomedical Acquisition vs. peers: Receivables Comparison

Loading

Eucrates Biomedical Acquisition Receivables Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

Eucrates Biomedical Acquisition (EUCR) FAQ

Eucrates Biomedical Acquisition (EUCR) currently reports a receivables of $0 as of December 2022. In the prior-year period, the figure was $0. Use the charts on this page to explore Eucrates Biomedical Acquisition's receivables history and peer comparisons.

Eucrates Biomedical Acquisition's receivables changed from $0 to $0 (period ending December 2022). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Eucrates Biomedical Acquisition reported $0 in receivables as of December 2022. In the prior-year period, the figure was $0. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current receivables of $0, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Eucrates Biomedical Acquisition, and consider following EUCR for alerts when major investors trade the stock.